$ATRC

Yuen Maggie sold $134K of ATRC

Yuen Maggie sold 3,500 shares of AtriCure, Inc. (ATRC) at $38.42 ($0.13M total) on 2026-08-05.

Original reporting
SEC EDGAR · Yuen Maggie
Published Aug 7, 2026, 1:18 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 1:23 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ATRC
Neutral
low confidence
Mentioned
$ATRC
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATRCNeutralLow
01

Why it matters

The only new information is the director’s sale size, price, and post-transaction holdings; it does not include guidance, clinical, regulatory, or deal updates.

02

Market read

Traders may note insider selling as a sentiment datapoint, but there is no fundamental catalyst in the filing.

03

What to watch

No 10b5-1 plan is disclosed, but insider sales can still be scheduled or driven by personal tax/financial planning; without additional context, signal quality is low.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-07, sale dated 2026-08-05

Background

The article is a SEC Form 4 insider transaction disclosure for AtriCure, Inc.

Company-level read

Ticker impact

$ATRCNeutralLow confidence
Context

AtriCure director Yuen Maggie sold 3,500 shares on 2026-08-05 at $38.42, totaling $134,470, per Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than earnings or guidance-related.

Evidence & confidence

Form 4 insider sales are common and often non-informational; the filing provides transaction details but no new company-specific operating or financial information.

Market effects

No clear sector read-through from a single director sale.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity or diversification, especially since the filing does not state any adverse company development.

Key entities

  • AtriCure, Inc.

    US-listed company whose director insider sale is disclosed via Form 4.

  • Yuen Maggie

    Director who sold 3,500 shares at $38.42 on 2026-08-05.

Related articles

$ATRCHigh

AtriCure, Inc. (ATRC): Results of Operations and Financial Condition

AtriCure, Inc. (ATRC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-7232026.htm EX-99.1 Document Exhibit 99.1 For immediate release July 23, 2026 AtriCure Reports Second Quarter 2026 Financial Results • Second Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year • Second Quarter 2026 profitabi